Moss, 21 August 2020
Gentian Diagnostics AS announces its results for the second quarter and first half of 2020. The highlights include:
- Record sales revenues of MNOK 16.6 in 2Q20, up from MNOK 10.2 in 2Q19
- Sales growth in 2Q20 of 64 % is especially based on Cystatin C sales in Asia. Sales in the quarter grew by 44 % YoY on a currency neutral basis
- Successful release of fPELA® turbo, which is marketed by our partner BÜHLMANN
- Gentian awarded up to MNOK 8.0 in funding to support the development of a high-throughput SARS-CoV-2 antibody test
- New scientific publications propose calprotectin as a promising biomarker for the management of COVID-19 patients, which represents a new opportunity for our GCAL® assay
Please find the report and results presentation here:
GDAS Interim Report 2Q 2020
GDAS Interim Presentation 2Q 2020
For further information, please contact:
Hilja Ibert CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525
MeldingsID: 511876
UtstederID: GENT-ME
Marked: Merkur Market